We and others have demonstrated that ChREBP potently transactivates expression of the metabolic hormone FGF21, and FGF21 is under investigation as a therapeutic for treatment of NAFLD (87, 91, 96, 97, 98, 99, 100). The gene discussed is MLXIPL; the disease is metabolic dysfunction-associated steatotic liver disease.